Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Dec 28, 2024 6:14pm
210 Views
Post# 36379628

RE:RE:RE:RE:RE:JP Morgan healthcare conference

RE:RE:RE:RE:RE:JP Morgan healthcare conferenceNo company with a de-risked late-stage Phase 2 platform technology centered around a single novel biologic product that can be used to treat multiple cancers with unmet medical needs, and that is ready to commercialize, would be seeking to license or arranging a "financing" deal at his time in the product's life-cycle,

Such development deals are conducted outside of a Business Development centric meeting like the 'premier'  JP Morgan Healthcare Conference, 
and without the need for the entire Executive team to be present. . JP Morgan is the largest and most important healthcare investment symosium in the world, and is a confrence where big Biopharma M&A deals are made.

ONCY has stated that they are ready to commercialize pelareorep and commercialization is done through a Big Pharma's marketing prowness and this happens when Big Pharma acquires such platform asset and brings that asset "in-house"  to market and develop further.
<< Previous
Bullboard Posts
Next >>